389 related articles for article (PubMed ID: 30013560)
21. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
22. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
23. Targeting neoantigens for cancer immunotherapy.
Zhao X; Pan X; Wang Y; Zhang Y
Biomark Res; 2021 Jul; 9(1):61. PubMed ID: 34321091
[TBL] [Abstract][Full Text] [Related]
24. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
25. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
[TBL] [Abstract][Full Text] [Related]
26. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
27. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.
Morisaki S; Onishi H; Morisaki T; Kubo M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Tsujimura K; Yoshimura S; Yew PY; Kiyotani K; Nakamura Y; Nakamura M; Kitazono T; Morisaki T
Front Immunol; 2023; 14():1223331. PubMed ID: 37881436
[TBL] [Abstract][Full Text] [Related]
28. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
29. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
30. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
[TBL] [Abstract][Full Text] [Related]
31. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
32. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
33. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
[TBL] [Abstract][Full Text] [Related]
34. Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets.
Xu C; Hong H; Lee Y; Park KS; Sun M; Wang T; Aikins ME; Xu Y; Moon JJ
ACS Nano; 2020 Oct; 14(10):13268-13278. PubMed ID: 32902245
[TBL] [Abstract][Full Text] [Related]
35. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
36. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
[TBL] [Abstract][Full Text] [Related]
37. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
38. Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma.
Wu M; Luo Z; Cai Z; Mao Q; Li Z; Li H; Zhang C; Zhang Y; Zhong A; Wu L; Liu X
EMBO Mol Med; 2023 Oct; 15(10):e16836. PubMed ID: 37552209
[TBL] [Abstract][Full Text] [Related]
39. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
[TBL] [Abstract][Full Text] [Related]
40. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Borden ES; Buetow KH; Wilson MA; Hastings KT
Front Oncol; 2022; 12():836821. PubMed ID: 35311072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
